AATS Wants to Improve Research in the Field of Cardiothoracic Surgery

Why It Matters

By combining AATS’s academic expertise with CTSN’s network and funding, the alliance can deliver higher‑quality, faster‑moving evidence that will shape future cardiothoracic guidelines and improve patient outcomes.

Key Takeaways

• AATS partners with CTSN to launch practice-changing trials
• Surgeons invited to propose trial concepts and technology innovations
• Collaboration enhances financial and intellectual resources for cardiothoracic research
• Network model accelerates multi‑site trial initiation and data collection
• Trials aim to shape future guidelines and AI‑driven care

Pulse Analysis

The American Association for Thoracic Surgery (AATS) has formalized a strategic alliance with the National Heart, Lung, and Blood Institute’s Cardiothoracic Surgical Trials Network (CTSN), a partnership that merges two of the most influential voices in cardiac and thoracic research. Since its inception in 2007, CTSN has enrolled roughly 20,000 patients across more than a dozen randomized trials, leveraging a shared clinical laboratory to bypass the costly setup of individual studies. By tapping into this existing infrastructure, AATS can immediately channel its academic expertise into large‑scale, practice‑changing investigations without reinventing the wheel.

Recruitment bottlenecks and fragmented long‑term outcome tracking have long hampered cardiothoracic surgery trials, limiting the speed at which evidence reaches the bedside. The new AATS‑CTSN Committee invites practicing surgeons to submit innovative trial concepts and emerging technology proposals, ensuring that study designs are rooted in real‑world clinical needs. Coupled with CTSN’s financial backing and multi‑site network spanning North America and Europe, the collaboration promises faster patient enrollment, standardized data capture, and the ability to pivot quickly when novel clinical questions arise, such as the integration of artificial intelligence into operative decision‑making.

Looking ahead, the joint effort is poised to influence national guidelines and set new standards for comparative‑effectiveness research in thoracic surgery. By fostering a culture of collaborative, data‑driven inquiry, AATS and CTSN aim to produce high‑quality randomized controlled trials that will inform device adoption, perioperative management, and postoperative surveillance for years to come. The partnership also signals a broader shift toward interdisciplinary alliances, where surgical societies, federal institutes, and industry partners co‑create evidence that balances innovation with patient safety, ultimately accelerating the translation of cutting‑edge therapies into everyday practice.